GCG and type 2 diabetes mellitus: Studies on insulinotrophic and anorexigenic effects of GLP-1 only recently have led to the development of a new class of drugs, often referred to as incretin drugs, which act as GLP-1 receptor agonists (GLP-1RAs) and are currently implemented in therapy for T2DM [13].